Founded only in 2020 and based in Champaign, Illinois, Orthogonal Biologics had been structured around employing the expertise of company personnel in protein engineering to make protein drugs that bind the virus spike with high affinity and specificity for safe and effective therapeutics. In early December 2021, it was announced that the firm had been acquired by Cyrus Biotechnology having expertise in Protein engineering, Rosetta design, biologics optimization, protein purification, bioinformatics. Terms of the transaction were not disclosed.
